LS Investment Advisors LLC increased its holdings in Catalent Inc (NYSE:CTLT) by 3.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,935 shares of the company’s stock after purchasing an additional 248 shares during the quarter. LS Investment Advisors LLC’s holdings in Catalent were worth $378,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. Magnetar Financial LLC grew its stake in shares of Catalent by 340.9% in the second quarter. Magnetar Financial LLC now owns 104,480 shares of the company’s stock worth $5,664,000 after purchasing an additional 80,782 shares during the last quarter. Bailard Inc. bought a new stake in Catalent during the 2nd quarter valued at approximately $379,000. Virginia Retirement Systems ET AL boosted its position in Catalent by 19.3% during the 2nd quarter. Virginia Retirement Systems ET AL now owns 22,300 shares of the company’s stock valued at $1,209,000 after acquiring an additional 3,600 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Catalent by 2.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,553,474 shares of the company’s stock valued at $84,214,000 after acquiring an additional 32,691 shares in the last quarter. Finally, Global Thematic Partners LLC bought a new stake in Catalent during the 2nd quarter valued at approximately $5,539,000.
Shares of CTLT opened at $49.25 on Friday. The company has a quick ratio of 1.70, a current ratio of 2.06 and a debt-to-equity ratio of 2.74. The business’s 50 day moving average price is $49.12 and its 200-day moving average price is $50.55. Catalent Inc has a 52 week low of $29.23 and a 52 week high of $58.38. The stock has a market cap of $7.38 billion, a P/E ratio of 30.40, a P/E/G ratio of 2.47 and a beta of 1.69.
In related news, Director Gregory T. Lucier purchased 2,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were purchased at an average cost of $51.64 per share, with a total value of $103,280.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John R. Chiminski sold 97,043 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $48.84, for a total value of $4,739,580.12. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.
Several analysts have weighed in on CTLT shares. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Robert W. Baird lifted their price objective on Catalent from $50.00 to $60.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. ValuEngine cut Catalent from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. UBS Group lifted their price objective on Catalent to $64.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Finally, Morgan Stanley lifted their price objective on Catalent from $50.00 to $61.00 and gave the company an “overweight” rating in a research report on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $56.25.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: What Factors Can Affect Return on Equity?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.